GSA Capital Partners LLP Takes Position in Avanos Medical Inc (AVNS)
GSA Capital Partners LLP purchased a new position in Avanos Medical Inc (NYSE:AVNS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,910 shares of the company’s stock, valued at approximately $1,364,000.
Other hedge funds have also made changes to their positions in the company. Bollard Group LLC purchased a new stake in Avanos Medical in the third quarter worth $100,000. Whittier Trust Co. purchased a new stake in Avanos Medical in the third quarter worth $110,000. Public Employees Retirement System of Ohio purchased a new stake in Avanos Medical in the second quarter worth $136,000. CENTRAL TRUST Co purchased a new stake in Avanos Medical in the third quarter worth $167,000. Finally, Bank of Montreal Can purchased a new stake in Avanos Medical in the third quarter worth $197,000. 88.96% of the stock is owned by institutional investors.
In related news, CEO Joseph Fralin Woody purchased 3,500 shares of Avanos Medical stock in a transaction dated Wednesday, November 28th. The stock was purchased at an average cost of $43.35 per share, for a total transaction of $151,725.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Steven E. Voskuil purchased 2,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 27th. The shares were bought at an average price of $43.74 per share, with a total value of $87,480.00. The disclosure for this purchase can be found here. Insiders have acquired 6,500 shares of company stock valued at $286,685 in the last three months. Insiders own 1.44% of the company’s stock.
Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.28 by $0.09. The business had revenue of $165.10 million during the quarter, compared to analyst estimates of $166.57 million. Avanos Medical had a return on equity of 6.59% and a net margin of 14.26%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. Sell-side analysts anticipate that Avanos Medical Inc will post 1.83 EPS for the current year.
A number of brokerages recently commented on AVNS. Raymond James raised Avanos Medical from a “market perform” rating to an “outperform” rating in a research note on Tuesday, August 21st. Zacks Investment Research lowered Avanos Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Morgan Stanley raised their price objective on Avanos Medical from $60.00 to $62.00 and gave the company an “underweight” rating in a research report on Thursday, October 11th. Barclays initiated coverage on Avanos Medical in a research report on Monday, October 15th. They set an “equal weight” rating and a $69.00 price objective for the company. Finally, TheStreet lowered Avanos Medical from a “b-” rating to a “c” rating in a research report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $69.25.
WARNING: “GSA Capital Partners LLP Takes Position in Avanos Medical Inc (AVNS)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2018/12/08/gsa-capital-partners-llp-takes-position-in-avanos-medical-inc-avns.html.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Featured Story: How to interpret a stock’s beta number
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.